ViroPharma VPHM
-
5 Biotech Stocks At Rock Bottom Price With Takeover Possibility
By StockPandit : So far, 2012 has been the best year for the Biotechnology and Drugs industry. So many stocks have surged in the last four months based on clinical trial results, U.S. Food and Drug Administration (FDA) approval, FDA Advisory Committee's recommendation, European commission approval,
-
3 Highly Shorted Biotech Stocks Being Bought Up By Insiders
By Kapitall : Do you consider yourself a contrarian? If you look for investing opportunities against the market's trends, your answer might be yes. We ran a screen with this idea in mind, beginning with the biotech industry. We screened US-traded biotech stocks for those with currently bearish ...
-
New Morningstar Analyst Report - ViroPharma , Inc.
… in midstage testing, the future of ViroPharma 's lead pipeline candidate maribavir ..... transplant patients in a Phase III trial. ViroPharma and Wyeth (now a part of Pfizer) broke ..... liver toxicities, casting doubt on ViroPharma 's ability to internally develop successful …
-
UPDATE 2- ViroPharma misses estimates, shares fall
May 1 (Reuters) - ViroPharma Inc's quarterly profit missed analysts' estimates on weak sales of its genetic disorder drug Cinryze and off-patent antibiotic Vancocin, sending its shares down 12 percent.
-
Weaker-than-expected Q1 results weigh on shares of ViroPharma ([[ VPHM ]] -9.5%), which has already dropped nearly 30% in the past month as what has been the drug devloper’s biggest seller, Vancocin, ...
… Weaker-than-expected Q1 results weigh on shares of ViroPharma ( VPHM -9.5% ), which has already dropped nearly 30% in ..... potential generic competition. Citing the generic threat, VPHM cuts its 2012 revenue target by nearly 25%. Post your …
-
Premarket gainers: [[PLXT]] +65%. [[PFCB]] +30%. [[NUVA]] +18%. [[CAR]] +14%. [[CETV]] +15%. [[VECO]] +13%. [[HUN]] +10%. [[YGE]] +8%. [[LYG]] +7%. [[SHLD]] +7%. [[CAKE]] +6%. [[TSL]] +6%. [[HTZ]] ...
… AKAM +4% . ARNA +4% . FSLR +3% . JASO +3% . CLWR +3% . PWER +3% . Losers: COP -22% . PBY -21% . IDTI -12% . VPHM -11% . NG -7% . DPZ -7% . WMS -6% . EMR -5% . XRAY -4% . NMR -4% . NZGA -3% . URI -3% . AVP -3% . ACI -3 …
-
ViroPharma Disappoints in 1Q; Generic Competition Should Result in Future Earnings Pressure
ViroPharma VPHM reported lackluster first-quarter ..... over the same period in 2011. Both of ViroPharma 's core products reported disappointing ..... draw-down issues weighed on sales ( ViroPharma used channel inventory to meet growing …
-
ViroPharma ( VPHM ): Q1 EPS of $0.37 may not be comparable to consensus of $0.42. Revenue of $135.8M (+7.1% Y/Y) misses by $14M. (PR)
ViroPharma ( VPHM ): Q1 EPS of $0.37 may not be comparable to consensus of $0.42. Revenue of $135.8M (+7.1% Y/Y) misses by $14M . ( PR ) Post your comment!
-
A Halo Comes Off
By InsiderInsights : The "risk-off" investment climate in April only exacerbated the recent woes of Halozyme Therapeutics ( HALO ). Halozyme's shares were momentum darlings entering the month. What's more, a savvy biotech insider had been averaging up the price of his holdings since last summer. ...
-
Notable earnings before Tuesday’s open: [[ACI]], [[ADM]], [[ADP]], [[AGCO]], [[AMG]], [[ARW]], [[AVP]], [[BDX]], [[BIIB]], [[BP]], [[CCJ]], [[CIE]], [[CMI]], [[DPZ]], [[ECL]], [[EMR]], [[ENDP]], ...
… DPZ , ECL , EMR , ENDP , FE , FWLT , HCP , HRS , HSP , HUN , LM , MLM , MMC , NI , PFE , PLD , SIRI , TLM , TRI , TRW , VLO , VPHM , WEC , [[]], [[]], [[]], [[]], [[]], [[]], [[]], [[]], [[]], [[]] Post your comment!